Published Date: 01 Mar 2023
Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.
Read Full News1.
Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma
2.
Elder Abuse: Red Flags to Look Out For While Receiving Care.
3.
Researchers can now forecast how prostate cancer bone metastases will react to radium-223 treatment.
4.
Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma
5.
Scientists pioneer noninvasive 3D imaging to enhance skin cancer management
1.
Essential Applications in Oncology in Daily Practice
2.
Decoding Granular Cell Tumor: What You Need to Know
3.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
4.
The Different Types of Cysts and Why They Occur: Insights from a Dermatologist
5.
Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation